Combined Therapy Effective in Reducing Urinary Albumin-to-Creatinine Ratio
The article reports on a study published in the American Journal of Nephrology, which found that combined therapy consisting of angiotensin receptor blockers and dipeptidyl peptidase-4 inhibitors was effective in reducing the urinary albumin-to-creatinine ratio (UACR) in patients with type 2 diabetes and chronic kidney disease. The study also found that the combined therapy was well-tolerated and did not increase the risk of adverse events compared to monotherapy with either drug. UACR is an important biomarker for kidney damage and a predictor of cardiovascular events. The study’s findings suggest that combination therapy may offer a promising approach to managing UACR and reducing the risk of complications in this patient population.